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Abstract
Background: Viperin, also known as RSAD2, is an interferon-inducible protein that potently restricts a broad range
of different viruses such as influenza, hepatitis C virus, human cytomegalovirus and West Nile virus. Viperin is
thought to affect virus budding by modification of the lipid environment within the cell. Since HIV-1 and other
retroviruses depend on lipid domains of the host cell for budding and infectivity, we investigated the possibility
that Viperin also restricts human immunodeficiency virus and other retroviruses.
Results: Like other host restriction factors that have a broad antiviral range, we find that viperin has also been
evolving under positive selection in primates. The pattern of positive selection is indicative of Viperin's escape from
multiple viral antagonists over the course of primate evolution. Furthermore, we find that Viperin is interferoninduced in HIV primary target cells. We show that exogenous expression of Viperin restricts the LAI strain of HIV-1
at the stage of virus release from the cell. Nonetheless, the effect of Viperin restriction is highly strain-specific and
does not affect most HIV-1 strains or other retroviruses tested. Moreover, knockdown of endogenous Viperin in a
lymphocytic cell line did not significantly affect the spreading infection of HIV-1.
Conclusion: Despite positive selection having acted on Viperin throughout primate evolution, our findings indicate
that Viperin is not a major restriction factor against HIV-1 and other retroviruses. Therefore, other viral families are
likely responsible for the evolutionary signatures of positive selection in viperin among primates.

Background
Antiviral proteins engaged in virus-host interactions are
often locked in evolutionary "arms-races", which have
been referred to as "Red Queen” conflicts. Viral infections continuously exert immense selective pressures on
the host antiviral proteins to evolve adaptively. The signatures of these evolutionary conflicts can be inferred by
observing signals of adaptive evolution (also called positive selection) in antiviral genes that result from
repeated episodes of Darwinian selection due to past
viral infections [1]. Often, the exact amino acids under
positive selection can describe the sites and domains
involved in host-virus interaction [2-4]. Thus, a detailed
look at the evolutionary trajectory of an antiviral gene
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can provide valuable information about the viral pressures that shaped host evolution.
Viperin (Virus inhibitory protein, endoplasmic
reticulum-associated, interferon-inducible, also known
as RSAD2) is a host protein with broad antiviral activity
(reviewed in [5-7]). Viperin inhibits the release of a wide
range of viruses in cell culture including Influenza A
virus [8], Hepatitis C virus [9-11], and Japanese Encephalitis virus [12]. Moreover, viperin knockout mice demonstrate the importance of this protein in controlling
West Nile Virus pathogenesis in vivo [13]. In the case
of human cytomegalovirus (HCMV), Viperin has been
reported not only to inhibit the expression of late viral
gene products [14] but also to enhance HCMV infectivity by remodeling the cellular actin cytoskeleton [15].
The precise mechanism of the broad-spectrum antiviral function of Viperin remains unclear. However, one
model for Viperin antiviral activity links lipid raft disruption to the restriction of Influenza virus release [16].
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Lipid rafts are sphingolipid- and cholesterol-enriched
microdomains on the plasma membrane that have also
been implicated in a number of processes including
membrane signaling, polarization, and immunological
synapse function [17,18]. Additionally, lipid rafts also
play an important role in the entry and assembly stages
of viral replication [17,19]. Moreover, the host sterol biosynthesis pathway is downregulated in response to viral
infections as part of the innate immune response via type
I interferon signaling [20]. Viperin has also been shown
to directly inhibit farnesyl diphosphate synthethase
(FPPS), a cellular enzyme critically involved in the biosynthesis of isoprenoid-derived lipids [16]. This suggests
that the disruption of cellular lipid raft formation may
represent a generalized host defense against viruses. As
lipid rafts are thought to be sites of assembly and budding for HIV and other retroviruses [17,21-23], we investigated whether Viperin restricts HIV-1 and other
retroviruses.
We find that viperin, like other host restriction factors
against viruses, has evolved under positive selection in
primates. We find that Viperin inhibits the release of the
LAI strain of HIV-1. However, we show that HIV-1 and
SIV strains have intrinsic differences in their sensitivity
to Viperin, and most are unaffected by over-expression
of Viperin. Furthermore, we did not see an effect of
Viperin knockdown on HIV-1 growth. Collectively, our
findings suggest that Viperin is not a major restriction
factor against HIV-1 and retroviruses, and thus its positive selection must have been driven by other viral
pathogens.

Results
Viperin has been evolving under positive selection
in primates

A recurring theme of host restriction factors is that they
exhibit a strong signature of positive selection [24].
Given the remarkable breadth of viruses restricted by
Viperin [5,6,14,16], we hypothesized that viperin might
also be evolving under positive selection. To investigate
this possibility, we sequenced the viperin gene from 18
species of primates and obtained 2 sequences of prosimian viperin from Genbank (Figure 1A and Additional file
1: Figure S1). Together, these primate species span
around 60 million years of divergence. The phylogeny
constructed from the primate viperin sequences was
congruent with the generally accepted primate phylogeny [25] confirming that the sequences are orthologous. There was no evidence of recombination as
ascertained by a GARD analysis [26].
In order to determine the lineage-specific pressures on
the primate viperin gene, we performed a free-ratio analysis using the PAML program suite [27], which allows
an independent assignment of omega (dN/dS) ratios to
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each evolutionary branch of the primate phylogeny,
where dN/dS ratios > 1 are indicative of positive selection. Several branches of the phylogeny within the New
World monkeys, Old World monkeys, and hominoids
showed dN/dS ratios > 1 (Figure 1A, bold branches). For
instance, the branches leading up to Spider Monkey and
FLM have dN/dS ratios > 1, indicative of positive selection. To test whether Viperin was subject to episodic or constant selective pressures over primate
evolution, we compared the likelihood ratios of the
free-ratio model (Figure 1B, Model 1) where all
branches were allowed to have their own independent
dN/dS, versus a model where the entire phylogeny
had the same dN/dS value (Figure 1B, Model 0). We
found that the free-ratio model fit the data better although this was marginally significant (p = 0.08). We
therefore conclude that primate viperin has been
under ancient, episodic positive selection.
We also performed a maximum likelihood analysis
using codeml from the PAML program suite [27] that
allows for different dN/dS ratios across individual
codons, and found strong evidence that the viperin
gene has been evolving under positive selection in primates (Figure 1C). In order to determine which domain
(s) in Viperin are responsible for the signal of positive
selection, we examined each domain separately (the
N-terminal alpha helix domain, a short middle region,
the Radical S-adenosylmethionine (SAM) domain and a
flexible C-terminal domain (Figure 1D)). While the
N-terminal alpha helix was not under positive selection, the middle region, Radical SAM domain and
C-terminal flexible domain showed signs of positive selection with high confidence (Figure 1D). In particular,
five amino acid positions exhibit strong signals of positive selection (corresponding to residues 42, 51,
142,145, 352 in human Viperin). These five amino acid
residues were independently confirmed to be under
positive selection with strong significance by randomeffect likelihood (REL) analyses (data not shown) [28].
Importantly, removal of these five amino acids leads to
loss of the signature of positive selection from the analyses (Figure 1C), validating that the majority of the
positive selection was acting on these sites. The dispersed nature of these positively selected residues is
reminiscent of other broadly acting antiviral genes like
Protein Kinase R (PKR), wherein escape from viral antagonism drives the positive selection of PKR [29].
This is in contrast to other restriction factors like
TRIM5alpha, where a cluster of positive selectively
selected residues identifies the viral specificity domains
[4]. Therefore, we conclude that viperin has evolved
under positive selection, likely to escape viral antagonism by a variety of viral lineages over the course of primate evolution.
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Figure 1 Positive selection of primate viperin. (A) Cladogram of
20 primate viperin genes sequenced for the evolutionary analyses.
Free ratio analysis in PAML was used to calculate the ω (dN/dS)
ratios of individual branches. The corresponding ω ratios are shown
above each branch, and the number of non-synonymous changes
and synonymous changes are indicated in parentheses. Branches
with ω > 1 are highlighted in bold. In the case of no observed
synonymous changes, the ω ratio could not be calculated (indicated
by 'inf'). (B) Likelihood ratio test statistics for models of variable
selective pressures along branches of primate viperin genes are
shown, using a comparison between M0 (same dN/dS ratio for all
branches) and M1 (different dN/dS ratio for each branch, free-ratio).
(C) A schematic of Viperin protein domain structure is shown.
Residues under positive selection with high confidence (P > 0.95) are
indicated in symbols above the protein. The table summarizes the
likelihood ratio test statistics for models of variable selective pressure
among viperin sites (M7 vs M8). Similar results were obtained in a
comparison of M1 (neutral) versus M2 (selection) (data not shown).
The amino acid positions are annotated in reference to the human
Viperin sequence. (D) The table summarizes likelihood ratio test
statistics performed between the M7 (neutral) and M8 (selection)
models for the individual protein domains of viperin gene from 20
primate species.

cells. Primary CD4+ T cells and monocytes were isolated
from peripheral blood mononuclear cells of two donors
and treated with interferon β for twenty hours. We
found that both primary CD4+ T cells and monocytes
express endogenous Viperin after induction with interferon (Figure 2A), but expression levels were undetectable in the absence of interferon.

Viperin inhibits HIV-1 Lai virus release

Given the broad antiviral range of Viperin, we wished to
investigate whether Viperin might also be relevant to
restricting HIV-1 infection. We first studied whether
Viperin is expressed at the protein level in HIV-1 target

Figure 2 Viperin expression in HIV-1 target cells. (A) Viperin
expression in HIV-1 primary target cells was determined by Western
blot analysis. CD4+ T cells and monocytes isolated from two donorderived peripheral blood mononuclear cells were treated with or
without interferon β1b induction (500 IU/ml) for twenty hours. (B)
Western blot analysis of endogenous Viperin expression in primary
CD4+ T cells and U937 cells treated with interferon β1b (500 IU/ml)
was compared to the transient expression of Viperin (3-fold serial
dilutions: 0, 0.01, 0.03, 0.1, 0.3, 1.0 μg) transfected in 293T cells.
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Figure 3 Effect of Viperin on virus release. (A) The effect of
viperin was measured by the infectious virus yield. 293T cells cotransfected with 200 ng of HIVLai or HIVLaiΔNef with serial dilutions
of human viperin was titered by infecting TZM.BL indicator cells. The
infectivity readout by β-galactosidase activity measured in relative
light units (RLU) is shown on the left, and the respective viruses
were normalized to β-galactosidase activity in the absence of viperin
as shown on the right. Error bars indicate standard deviations from
three infection replicates; this data are representative of five
independent experiments. (B) Western blot analysis was performed
on the cell-free virus and cellular extracts, and probed with α-p24
antibody. Viperin expression in the cellular extracts is shown, and
actin was probed as a loading control. This blot is representative of
four independent experiments. (C) The effect of Viperin on the
specific infectivity of virus particles was calculated. HIVLai or
HIVLaiΔNef virus from 293T cells co-transfected with or without
Viperin (700 ng) was titered by infecting TZM.BL indicator cells as
shown on the left. Virus release in the cell-free supernatant was
quantified by p24 ELISA as shown in the middle. The specific
infectivity was calculated as ratio of β-galactosidase activity (RLU)
over the amount of p24 (ng/ml), as shown on the right. Error bars
indicate standard deviations of triplicate infections; the data are
representative of at least three independent experiments. (D) Virus
yield from 293T cells co-transfected with a combination of Tetherin
(50 ng) or Viperin (700 ng) was titered on TZM.BL cells. Fold
inhibition was calculated in comparison to virus yield in absence of
Tetherin/Viperin. Error bars indicate standard deviations of triplicate
infections; the data are representative of three independent
experiments.

Given that Viperin is under positive selection and
expressed in HIV-1 primary target cells after interferon induction, we investigated whether Viperin restricts HIV-1.
To begin these studies, we first compared levels of endogenous Viperin expression with levels achieved by
transfection of the cloned human viperin gene into 293T
cells. We found that untransfected 293T cells express undetectable levels of endogenous Viperin. However, the
transient expression of Viperin in 293T cells transfected

with between 0.3 and 1 μg of DNA bracketed the amount
of endogenous Viperin expression in primary CD4+ T
cells and U937 cells when induced with interferon
(Figure 2B). Therefore, in subsequent studies, we used
amounts of the plasmid encoding the human viperin gene
that gave levels of Viperin expression just below and just
above the levels expressed in primary cells.
We tested whether exogenous Viperin expression could
restrict HIV-1 by co-transfecting 293T cells with a fulllength HIV-1 Lai provirus with increasing amounts of the
human viperin gene. Additionally, we tested HIV-1 Lai
lacking a nef gene, since Nef has been implicated in
modulating cellular cholesterol levels [30,31]. We measured the antiviral activity of Viperin by infecting TZM.BL
indicator cells with released virus, and assaying for βgalactosidase reporter activity (See Methods). We found
that wild-type HIV-1 virus was marginally affected at low
amounts of Viperin, but was inhibited at the highest dose
of Viperin (Figure 3A, closed circles). Consistent with the
known defect on virion infectivity in the absence of Nef
[32], the HIVΔNef virus had a lower infectivity even in
the absence of Viperin as measured by the β-galactosidase
activity (Figure 3A left, compare closed circles and open
circles at 0 μg viperin). Despite that initial observation, the
HIVΔNef virus was restricted further by viperin in a dosedependent manner (Figure 3A, open circles). To compare
the degree of restriction between the two viruses, we normalized the β-galactosidase reporter activity of each virus
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to their measurements in the absence of Viperin
(Figure 3A right). We observed that the wildtype HIV
virus was only restricted at the highest levels of Viperin
expression, whereas the HIVΔNef virus was more sensitive to Viperin restriction than wildtype HIV, even at the
lower levels of Viperin expression.
Because Viperin restricts influenza virus at the step of
virus release [16] and HCMV by inhibiting the production of viral structural proteins [14], we investigated
whether HIV-1 production and/or release is affected by
Viperin by Western blotting for cell-associated and cellfree Gag proteins. We hypothesized that if Viperin
affects HIV production; we expected to see a decrease in
intracellular p55gag expression that correlates with a decrease in cell-free p24gag. Conversely, if Viperin affects
virus release, we would see lower levels of cell-free
p24gag while levels of p55gag would remain unchanged.
We found that cell-associated HIV-1 p55gag for both
WT and ΔNef virus was only marginally affected by the
expression of Viperin (Figure 3B). Moreover, cell-free
levels of p24gag from wild type HIV-1 were modestly
affected by the expression of Viperin (Figure 3B) in a
manner consistent with a slight decrease in the amount
of supernatant HIV p24gag when measured with an
enzyme linked immunosorbent assay (ELISA) assay
(Figure 3C, middle). However, Viperin expression
showed a drastic reduction in cell-free HIVΔNef p24gag
(Figure 3B, right), with only a small effect on intracellular p55gag levels (Figure 3B, left). This suggests that
Viperin affects release of HIVΔNef virus.
Since Viperin might also be affecting the quality of
the virus particles, we quantified the specific infectivity
of virus particles by measuring the ratio of infectious
titer to relative particle production (by p24 ELISA).
Consistent with other studies, we found that wildtype
HIV virus was more infectious than HIVΔNef virus
(Figure 3C). However, viperin expression did not affect
the specific infectivity (infectivity divided by p24gag) of
either wildtype HIV virus or HIVΔNef virus particles
(Figure 3C, right), indicating that the Viperin-mediated
restriction of HIV-1 is not due to a reduction in viral
infectivity.
Since Viperin seemed to affect virus release, we compared Viperin restriction to that of Tetherin, a wellcharacterized host restriction factor that inhibits virus
release [33,34]. Virus restriction by a combination of
Viperin and Tetherin expression was roughly additive
(Figure 3D). Furthermore, the response of Viperin and
Tetherin is different since HIV-1 Vpu abrogates
Tetherin restriction but has no effect on Viperin restriction, whereas HIV-1 Nef abrogates Viperin restriction
(Figure 3D). These results suggest that Viperin restricts
HIV-1 release by a mechanism that is distinct from the
pathway used by Tetherin.
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Most HIV strains, SIVs and retroviruses are resistant to
Viperin restriction

To examine the breadth of Viperin restriction on HIV-1
we tested several strains of HIV-1 for their susceptibility
to Viperin restriction on virus release. The proviruses
were deleted of their nef gene to exclude the possible
confounding effects of Nef specificity. Consistent with
the earlier experiments (Figure 3C), HIVLaiΔNef virus
release was inhibited by human Viperin. However, virus
release of the HIVΔNef NL4-3, SF162 (both HIV-1 subtype B) and Q23-17 strains (HIV-1 subtype A) were unaffected by Viperin expression (Figure 4A). To verify
these observations, we performed a Western blot analysis comparing the cell-associated and cell-free HIV-1
Gag protein levels. In contrast to the dose-dependent
inhibition of HIVLaiΔNef virus release, cell-free
HIVNL4-3ΔNef virus release remained unaffected
(Figure 4B). While there was an observable effect on
intracellular HIVNL4-3ΔNef virus p55 levels, this difference was not reflected in the cell-free Gag p24 levels or
the ELISA assay. In addition, we tested an HIV-1 vector
encoded from a codon-optimized Gag-pol sequence
called pCNC-SynGP [35]. We observed that the cellfree HIV-1 pCNC-SynGP Gag was unaffected by
Viperin expression. Instead, cell-associated p55gag protein production was slightly increased in the presence
of Viperin expression. As for the HIVΔNef SF162 and
Q23-17 strains, there were no significant effects on cellfree p24gag or cell-associated p55gag expression levels.
One exception is a noticeable decrease in the partially
processed, cell-associated, HIVΔNef SF162 p40gag
levels. However, while Viperin might have a subtle effect
on the intracellular Gag levels of certain HIVΔNef
strains, the difference was not reflected in the cell-free
virus or measured in the ELISA assay. Thus, it appears
that Viperin does not significantly impact the virus release of most HIVΔNef strains tested except for the
HIV-1 Lai strain.
We next investigated the ability of Viperin to restrict
related simian immunodeficiency virus (SIV). In addition
to their nef gene deletion, the proviruses were also pseudotyped with VSV-G so that the entry of all viruses
would be equal. Using an infectivity assay, we found that
SIVmac239ΔNef was as sensitive to Viperin as HIV1LaiΔNef (Figure 4C, open squares). However, SIVagmTAN1ΔNef, SIVcpzTAN3.1ΔNef and HIV-2ROD9ΔNef
were resistant to Viperin restriction. Since Viperin did
not appear to restrict the majority of primate lentiviruses
we tested, we also examined two additional divergent
retroviruses – murine leukemia virus (MLV) and feline
immunodeficiency virus (FIV). In contrast to the control
HIVΔNef Lai virus, MLV and FIV were unaffected by
Viperin expression (Figure 4D), indicating that Viperin
does not generally restrict retroviruses. Thus, while
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Figure 4 Human viperin is not a general inhibitor of HIV/SIV. A panel of HIV-1ΔNef strains was tested for their sensitivity to Viperin
overexpression. (A) Virus release was assayed by p24 ELISA quantification of cell-free supernatant forty-eight hours after co-transfection of 293T
cells. Error bars indicate standard deviations of three replicates and are representative of three independent experiments. (B) Western blot analysis
was performed on the cell-free virus and cellular extracts of (A). HIV-1 Gag expression was assessed by α-p24 antibody. Viperin expression in the
cellular extracts is shown, and Actin was probed as a loading control. This blot is representative of at least three independent experiments. (C)
Single-cycle infectious virus yield of VSV-G pseudotyped primate lentiviruses from 293T cells co-transfected with serial titration of Viperin and was
titered on TZM.BL indicator cells. Proviruses were deleted of the nef gene. The infectivity readout by β-galactosidase activity was measured in
relative light units (RLU). (D) The effect of Viperin on retroviruses was measured by co-transfecting 293T cells with MLV, FIV or HIVLaiΔNef with
serial titrations of Viperin. Viruses were pseudotyped with VSV-G and titered by infecting HeLa cells. The expression of virus-encoded GFP was
quantified by flow cytometry. This analysis is representative of at least three independent experiments. (E) Schematic of chimeric proviruses of
HIVLai and HIVNL4-3 highlighting the breakpoint and features in the non-coding region of the provirus. Single-cycle infectious virus yields from
co-transfected 293T cells were assayed by titering on TZM.bl reporter cells. Error bars indicate standard deviations of four infection replicates, and
the data are representative of at least three independent experiments.

Viperin may inhibit a limited subset of primate lentivirus
strains (HIV-1Lai and SIVmac239, for example), the majority of HIV-1 strains, SIVs and retroviruses that we
tested are not affected by Viperin expression.
The difference in restriction profiles between Lai and
NL4-3 strains was unexpected since NL4-3 is a recombinant virus of NY5 and Lai strains [36]. We attempted
to map the viral determinant of Viperin sensitivity by
constructing a series of chimeric proviruses between Lai
and NL4-3 strains and tested them in an infectivity
assay. While we expected that changes in Gag proteins
previously associated with virus release might be

involved, chimeric proviruses within Gag failed to identify a determinant within Gag (data not shown). Instead,
we found that even when all coding regions were
swapped between the Lai and NL4-3 strains of HIV-1,
the sensitivity to Viperin restriction still mapped to Lai
sequences outside of the coding region (Figure 4E). That
is, when the coding region of HIVLai was expressed in
the context of HIV-1 NL4-3 non-coding region, sensitivity to Viperin restriction was lost. However, when we
inserted the non-coding region of HIV-1 Lai including
the LTRs, 5’ packaging region, and the PPT into HIV-1
NL4-3, then the virus was sensitive to inhibition by
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Viperin (Figure 4E). Thus, human Viperin displays differential restriction specificities against related HIV-1,
which is dictated entirely by non-coding regions of the
provirus. We conclude, therefore, that the restriction by
exogenous Viperin of HIV-1 is likely due to threshold
effects of expression, rather than due to direct interactions of Viperin with viral components.

for Viperin expression (Figure 5B). Considering that the
HIVLaiΔNef is the most sensitive strain in Viperin overexpression experiments (Figuresa 2 and 4), these results
suggest that endogenous levels of Viperin do not affect
spreading infection by HIV-1.

Knockdown of endogenous Viperin in a cell line does not
affect HIV-1 Lai

Most of the experiments that we have carried out were
using the human viperin allele. However, since viperin
evolves rapidly under positive selection, we might not be
accurately capturing the potential ability of Viperin proteins to restrict lentiviruses. The species-specificity of action is one of the key features that have emerged from
the study of rapidly evolving restriction factors. To address the possibility that the human Viperin might not
accurately capture the restrictive potential of Viperin, we
carried out two experiments to measure any functional
divergence between primate Viperin orthologs that may
have arisen from the positive selection.
First, we tested 5 additional Viperin orthologs against
the HIVLaiΔNef (Figure 6A). We found that all six
Viperin orthologs are able to restrict this virus to approximately the same extent, despite some variation in
the degree of restriction. This means that the positive selection of viperin does not manifest a functional difference in the degree of restriction of HIVLaiΔNef. Second,
we compared the human and rhesus orthologs against a
panel of viruses to assess whether we could discern any
key restriction differences between these two Viperin
orthologs (Figure 6B). It is notable that human versus
rhesus differences have been found in many positively
selected restriction factors that have been tested so far
[4,29,37]. However, in the case of Viperin, we found no
significant differences between the restriction profiles of
human and rhesus Viperin.
These results imply that Viperin's lack of restriction of
the majority of lentiviruses and retroviruses tested is
general to primate viperin genes. Moreover, this finding
strongly implies that gain or loss of lentivirus restriction
is not correlated with the dramatic evolutionary changes
we observed in the viperin gene in primates.

A more critical test of the physiological role of Viperin
on HIV-1 replication is to change levels of endogenous
Viperin in cells where spreading infections can be performed. To determine the effect of endogenous Viperin
on HIV-1, we sought to knock-down Viperin expression
with shRNAs. Unfortunately, we were unable to obtain
suitable stable or transient knockdown in primary T cells
(data not shown). Many T cell lines such as SupT1
cells also do not express Viperin after interferon induction (data not shown). However, CD4+ U937 monocytic cells do express Viperin after interferon induction
(Figure 2B). Using a stably transduced shRNA construct,
we were able to partially knockdown expression of
Viperin in U937 cells (Figure 5A). U937 cells that were
either knocked-down for Viperin (shRNAVip) or transduced with a control shRNA (shCON) were infected
with HIV-1LAI and HIV-1LAIΔNef at a multiplicity of
infection of 0.5. Infections were done in the presence of
interferon to induce Viperin expression. Viral supernatant was collected periodically over 11 days, and
spreading infection was monitored by p24 ELISA. We
found that there was no significant difference between
WT and ΔNef virus growth in the cells knocked-down

No functional divergence in lentiviral restriction among
primate Viperin orthologs

Discussion
Primate Viperin is not a lentiviral restriction factor
Figure 5 Analyses of endogenous Viperin activity. (A) Viperin
expression in U937 cells stably transduced with empty pGIPZ shRNA
vector (Ctl) or Viperin targeting shRNA (Vip) was analyzed by
Western blot twenty hours after interferon β1b treatment
(500 IU/ml). (B) Spreading infection of wildtype HIVLai or HIVLaiΔNef
was quantified by p24 ELISA at indicated time points after infecting
shRNA-transduced U937 cells at an moi of 0.5. Cells were maintained
in interferon β1b (500 IU/ml) for the duration of the experiment. The
data are representative of at least three independent experiments.

The restriction factor Viperin recognizes and restricts a
wide diversity of viruses, including both single-stranded
RNA and double-stranded DNA viruses [5-7]. This
broad repertoire of antiviral activity prompted us to investigate Viperin’s restrictive activity against retroviruses,
specifically the primate lentivirus lineage. We found that
Viperin is highly interferon-induced in primary target
cells of HIV. Viperin overexpression is able to inhibit
HIV-1 Lai replication by affecting virus release.

Lim et al. Retrovirology 2012, 9:55
http://www.retrovirology.com/content/9/1/55

A

Page 8 of 12

Luciferase activity (RLU)

5

10

4

10

3

10

2

10

Vector Human Rhesus AGM Colobus OwlM SpiderM

B
No Viperin

6

Human Viperin

Rhesus Viperin

Gal Activity (RLU)

10

5

10

4

10

3

10

2

10

HIV-1

SIV

HIV-1

HIV-1

HIV-1

SIV

HIV-2

SIV

Lai

MAC

NL4

Q23-17

SF162

CPZ

Rod9

AGM

Nef

Nef

Nef

Nef

Nef

Nef

Nef

Nef

Figure 6 The antiviral activity of primate Viperin orthologs was assayed. (A) 293T cells were co-transfected with HIVLaiΔNef that encodes a
luciferase reporter gene (200 ng) and the indicated primate Viperin (700 ng). Virus yield was measured by infecting SupT1 cells and assayed for
luciferase expression. Error bars represent standard deviations of four infection replicates and are representative of three independent
experiments. (B) Single-cycle infectious virus yield of VSV-G pseudotyped primate lentiviruses from 293T cells co-transfected with 700 ng of
human Viperin, rhesus Viperin or empty vector was titered on TZM.BL indicator cells. The infectivity readout by β-galactosidase activity was
measured in relative light units (RLU). Error bars indicate standard deviations of four infection replicates, and are representative of at least three
independent experiments.

However, most other strains of HIV-1, SIV and other
retroviruses are unaffected by primate Viperin orthologs.
Finally, we could not find an effect on spreading infections of HIV-1 Lai in U937 cells after knockdown of endogenous Viperin levels. Therefore, we conclude that
Viperin is not a major restriction factor against HIV-1
and other primate lentiviruses. These results emphasize
the fact that broadly acting innate host defense genes do,
nonetheless, have viral specificity that goes beyond their
escape from viral antagonism.
Lipid rafts play an important role in virus replication
and are actively regulated as part of the host response to
viral infection [20]. As Viperin inhibits Influenza virus
release by impairing the lipid metabolic pathway enzyme
FPPS resulting in the disruption of lipid rafts [16], we
expected that it would have a broad antiviral role in
inhibited viruses that bud through lipid rafts, in a way
similar to how Tetherin affects many different enveloped
viruses that bud through the plasma membrane [38].
However, importantly, we did not find this to be the case
since HIV was generally resistant to the effects of
Viperin. Thus, these data argue that it is overly simplistic

to characterize all viral lipid raft interactions as equivalent, but rather there are likely important differences in
the lipid requirements for budding of different virus
families. It may be important that unlike HIV, influenza
assembly at lipid rafts does not involve the ESCRT machinery [39].
A previous study that showed that poly I:C-induced
Viperin had a subtle effect on HIV-1 infection in astrocytes [40]. However, our findings are not consistent with
an effect of Viperin on HIV-1 replication in general. Although other retroviral restriction factors appear to be
active in all cells tested, it is possible that the antiviral
effects of Viperin are cell-specific and would be active in
primary cells that were not able to be tested in this
study. Furthermore, it is formally possible that all of the
retroviruses tested encode an antagonist of Viperin that
abrogates its action. However, virus-host antagonism
should show species-specificity [1]; we believe that this
is very unlikely because viperin cloned from a wide
range of different primates showed equivalent activities
against HIV-1 and diverse retroviruses (Figure 6 and
data not shown), and Viperin expression is not affected
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by co-transfection with proviruses (data not shown).
Nonetheless, the fact that we did find two lentiviral proviruses encoded by HIV- 1 Lai and SIVmac239 that were
inhibited by transfection of viperin, suggests that the
pathway used by Viperin must at least peripherally intersect with lentiviral production.
Our findings of Viperin restriction of the Lai strain of
HIV-1 but not the NL4-3 strains are unexpected since
NL4-3 is a recombinant virus of NY5 and Lai strains
[36]. We have mapped the genetic basis of the susceptibility difference to a non-coding region of the virus.
Moreover, we found that HIV-1Lai with a deletion in
Nef was more sensitive to Viperin than a full-length provirus. Complementation of the Lai strain of HIV-1 ΔNef
provirus with Nef in trans partially restored the resistance to Viperin (data not shown). One possible explanation is that LTR promoter efficiency and the presence
of Nef may affect viral Gag production in a manner that
renders it sensitive to Viperin. Alternatively, we believe
it is more likely that less infectious viral combinations
are more sensitive to perturbations caused by exogenous
expression of Viperin. Nonetheless, considering that
most strains of HIV-1, SIVs (excluding SIVmac239),
tested are resistant to Viperin, we favor the more parsimonious conclusion that Viperin is not a significant
player in the immune defense against lentiviruses. Moreover, the results describe here serve as an important
caution that over-expression systems with single isolates cannot be relied on to functionally identify and
characterize restriction factors.
Insight into viperin function from its positive selection

Antagonistic genetic conflicts between hosts and viruses
have driven rapid adaptive evolution of antiviral protein
which is characteristic of many retroviral restriction factors [24] as well as other antiviral factors that target a
broad range of viruses [29,41]. Like many host restriction factors, we find that viperin has been evolving
under positive selection in primates. The signatures of
rapid evolution in viperin may provide valuable information about the mechanism by which it restricts this
broad repertoire of viruses and likely avoids viral antagonism. This is analogous to the dynamics of the host restriction factor Tetherin, where the highest recurrent
signal of positive selection corresponds to the amino
acid that is a determinant for antagonism by Nef [3]. In
the antagonist-driven scenario, we speculate that the
amino acid residues under positive selection on Viperin
might have been driven by pressures to evade viral
antagonists and would be indicative of sites directly
involved in viral protein interactions. In this regard, the
evolution of primate Viperin may provide valuable clues
to virus families that have driven the positive selection
of Viperin throughout primate evolution [1,41] by
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finding which viruses encode antagonists to Viperin with
a specificity that is specified by the amino acids in
Viperin that are under positive selection. A promising
candidate would be Japanese encephalitis virus which
encodes an unidentified viral antagonist that degrades
Viperin in a proteasome-dependent mechanism [12].

Conclusion
We document an ancient, episodic and recurrent history
of adaptive evolution in Viperin over primate evolution.
However, despite the fact that Viperin restricts a wide
range of other virus families [15], it does not have a
major effect on HIV-1 and other lentiviruses, and therefore, the positive selection in viperin was likely driven by
selective pressures imposed by virus families other than
the lentiviruses.
Methods
Plasmids

Human Viperin was cloned from human cDNA derived
from 293T cells, and inserted into a retroviral expression
vector pLPCX as an untagged construct. The five primate Viperin orthologs were similarly cloned from
cDNA into the pLPCX retroviral expression vector as
untagged constructs. HIVLai, HIVLaiΔNef and HIVLaiΔVpuΔNef, SIVagmTANΔEnvΔNef were described
previously [3,42]. HIVNL4-3ΔNef was obtained from the
NIH AIDS Research and Reference Reagent Program,
11100. HIVSF62ΔNef was generated by fill-on of the
XhoI site (nt 8576) resulting in a 2bp frameshift mutation in the Nef open reading frame of the full length
HIV-1SF162 provirus [43]. HIV-1Q23-17ΔNef was constructed by introducing a luciferase gene in place of Nef
into the full length HIV-1 Q23-17 provirus [44].
SIVcpzΔNef was generated by introducing a luciferase
gene in place of Nef into the full length SIVcpzTAN3.1
provirus [45] (NIH AIDS Research and Reference Reagent Program, 11100) by overlapping PCR between the
NdeI and NheI region and sequence verified. HIV2Rod9ΔEnvΔNef was a gift from Masahiro Yamashita,
and SIVmac239ΔEnvΔNef was a gift from David Evans
[46]. pGIPZ vector-based control shRNA or shRNA
targeting Viperin mRNA (hairpin construct: TGCTG
TTGACAGTGAGCGCGATGAAAGACTCCTACCTTA
TTAGTGAAGCCACAGATGTAATAAGGTAGGAGTC
TTTCATCTTGCCTACTGCCTCGGA) were purchased
from FHCRC RNAi core facility.
Viral infectivity assay

293T cells were seeded at 1.67 x 105 cells/ml in 12-well
plates, and DNA was transfected with TransIT LT-1
(Mirius) according to the manufacturer's recommendations. The total amount of DNA in all transfections was
maintained constant with appropriate empty vectors.
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Forty-eight hours after transfection, supernatant was collected, filtered through a 0.2μM filter and serially diluted
for the following infectivity assay. SupT1 cells at 2.5 x
105 cells/ml in 96-well plates were as described previously [3], or TZM.bl cells at 1.0 x 105 cells/ml in 96-well
plate were as described previously [42]. The βGalactosidase activity was detected using the GalactoStar system (Applied Biosystems) according to the manufacturer's recommendations.
Virus release p24 ELISA

Virus were serially diluted and measured by HIV-1 p24
antigen capture assay (Advanced BioScience Lab Inc)
and detected with QuantaRed enhanced chemifluorescent HRP substrate (Thermo Scientific) according to the
manufacturer’s protocol.
Western blotting

Western blot analysis was performed as described previously [3,42] with the following antibodies: HA-specific
antibody (Babco), anti-Viperin (Enzo Life Sciences), antiactin (Sigma-Aldrich), anti-tubulin (Sigma-Aldrich), and
HIV-1 p24 antibody (NIH Aids Research and Reference Reagent Program, 183-H12-5C) [47]. Primary antibodies were
detected with a corresponding horseradish peroxidaseconjugated secondary antibody.
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from Coriell Cell Repositories (Camden, NJ): chimpanzee
(Pan troglodytes), gorilla (Gorilla gorilla), Sumatran
orangutan (Pongo pygmaeus), Siamang gibbon (Hylobates
syndactylus), agile gibbon (Hylobates agilis), rhesus macaque (Macaca mulatta), greater white-nosed monkey
(Cercopithecus nictitans), kikuyu colobus (Colobus guereza kikuyuensis), Francois' leaf monkey (FLM) (Trachypithecus francoisi), spider monkey (Ateles geoffroyi), owl
monkey (Aotus trivirgatus), dusty titi monkey (Callicebus
moloch) and woolly monkey (Lagothrix lagotricha).
Human (Homo sapiens), African green monkey (Chlorocebus aethiops) and Baboon (Papio anubis) Viperin were
amplified by reverse transcription-PCR (RT-PCR) from
an RNA extract of 293T cells, COS-7 cells and B-LCL
cells respectively. Viperin was amplified by RT-PCR with
a OneStep RT-PCR kit (Qiagen), and the cDNA derived
was directly sequenced. Viperin was amplified with "forward" primer (5'-ATGTGGGGTGCTTACACCTGCTG
CTTTTGCTG-3') or (5'-ATGTGGGTACTCACGCCTG
CTGCTTTTGCTG-3') in combination with "reverse"
primer (5'-CTACCAATCCAGCTTCAGATCAGCCTTA
CTC-3') or (5'-CTACCAATCCAGCTTCAGATCAGCC
TTACTC-3'). Sequences for prosimian grey mouse lemur
(Microcebus murinus) and tarsier (Tarsius syrichta)
viperin gene were obtained by tblastx search on the
NCBI database from cont1.216710 (ABDC01216711.1)
and contig1.93320 (ABRT010093321.1) respectively.

PBMC isolation and separation

Patient pall filters were obtained from Puget Sound
Blood Center. PBMCs were isolated by standard ficoll
histopaque gradient methods. Monocytes and CD4+ T
cells were isolated by Human CD14 selection and CD4+
magnetic bead isolation (EasySep), and the isolation purity (>97-99%) was confirmed by flow cytometry staining
(BD Pharmingen). Monocytes were maintained in RPMI
containing 10% FBS. CD4+ T cells were activated with
2.5μg/ml PHA and 20U/ml IL-2 for 3 days before interferon treatment. Monocytes and CD4+ T cells were treated with 500 IU/ml human interferon β1b for 20 hours,
followed by western blot analysis on total cell lysates.
Spreading infectivity assay

U937 cells stably transduced with either a Viperintargeting shRNA or control shRNA constructs were
infected with a wild type HIV-1Lai virus or HIV-1LaiΔNef
at a moi of 0.5. Cells were washed with PBS three times
and maintained in media containing 500 IU/ml human
interferon β1b throughout the course of the experiment.
Supernatant was collected at indicated time points and
virus was quantified by p24 ELISA.
Sequencing of primate viperin genes

The viperin genes from the following primates were
amplified from RNA isolated from cell lines obtained

Sequence analysis

DNA sequences were aligned by ClustalX [48] and were
edited manually. The amino acid positions are annotated
in reference to the human Viperin sequence. A phylogeny of viperin genes was constructed from DNA
sequences with ClustalX by the neighbor-joining method
using the Jukes Cantor method of correction and with
PhyML [49] by the maximum-likelihood method. The
two methods yielded trees with identical topologies.
Maximum-likelihood analysis was performed with
CODEML from the PAML suite of programs [27] as
previously described [2,3]. Sequence alignments were
obtained when the data were fitted with an F61 model of
codon frequency, and consistent results were obtained
when the data were fitted with an F3 x 4 model of codon
frequency. Viperin sequences were fitted to NSsites
models that disallowed (NSsites model 1 and 7) or permitted (NSsites model 2 and 8) positive selection. Likelihood ratio tests were performed to evaluate whether
permitting codons to evolve under positive selection
gave a better fit to the data. A cutoff of posterior probability of p > 0.95 was implemented in these analyses
(M8) to identify amino acid residues having evolved
under positive selection. Analyses were also validated
with REL from the HyPhy package [50]. Free ratio analysis in PAML was used to calculate the ω (dN/dS) ratios
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of individual branches. Likelihood ratio test statistics
was performed for models of variable selective pressures
along branches of primate viperin genes between M0
(same dN/dS ratio for all branches) and M1 (different
dN/dS ratio for each branch). The degree of freedom is
equal to one less than the total number of branches in
the phylogeny.
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The sequences of the 18 primate viperin genes have
been entered into the GenBank database under accession numbers NM_080657, JQ437821 to JQ437837.
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